Table 3.

Study endpoints

Primary endpoint

Prevalence of anti-SARS-CoV-2 nucleocapsid (N) protein antibodies (IgG and/or IgM positive) against SARS-CoV-2 among pregnant women at delivery.

Secondary endpoints

PCR-confirmed SARS-CoV-2 infection among pregnant women at recruitment. Incidence of SARS-CoV-2 infection during pregnancy. Maternal and neonatal morbidity and mortality due to SARS-CoV-2 infection during pregnancy. Pregnancy and perinatal adverse outcomes. Rate of vertical transmission of SARS-CoV-2 from infected mothers to their offspring during the prenatal and perinatal periods. CD4 cell counts and HIV viral load. Malaria parasitaemia at delivery (from maternal sample collected at delivery).